Psychotic disorder

Researchers are testing an experimental drug called LY2140023 in people with schizophrenia who have already completed a short-term trial of the same drug. The study compares LY2140023 to standard antipsychotic medications like olanzapine, aripiprazole, risperidone, and quetiapine…

Researchers are studying the long-term safety of pomaglumetad methionil, an experimental drug taken by mouth, in adults with schizophrenia. About 129 participants receive the drug and are monitored for up to five years. The study tracks movement side effects, weight, blood sugar,…

This trial is testing whether emraclidine, an experimental oral medication taken once daily for a year, is safe and tolerable for adults with schizophrenia. Participants who completed earlier studies of emraclidine may join, and researchers will monitor side effects, vital signs,…

This pilot study tested deep brain stimulation (DBS) in 15 people with treatment-resistant schizophrenia who still had severe hallucinations despite medication. The device was placed in a brain area linked to schizophrenia to try to calm symptoms. The study was terminated early, …

This study looked at the long-term safety of a medicine called iclepertin in adults with schizophrenia who had already finished earlier studies. About 1,356 participants took iclepertin tablets once a day for one year, along with their usual schizophrenia medications. The main go…

This study tested a dental health education program for people with schizophrenia to see if it could improve their oral hygiene and quality of life. Participants were randomly assigned to either the education program or standard monitoring. The study lasted 12 months and included…

This study tested a combination of long-acting injectable antipsychotic medication and cognitive/functional skills training in people with early schizophrenia. The goal was to see if this approach helps patients achieve stable symptom remission and improve daily functioning. Only…

This study tested cariprazine (VRAYLAR), an approved schizophrenia drug in the U.S., for people with acute schizophrenia in Japan and Taiwan. Participants received either cariprazine or a placebo for 6 weeks, then could continue on cariprazine for 18 more weeks. The trial was ter…

This study aimed to see how two antipsychotic drugs, aripiprazole and ziprasidone, affect heart risk in people with schizophrenia, schizoaffective disorder, or bipolar disorder. Researchers measured blood fats and heart electrical changes in 48 adults over 12 months. The trial wa…

This early pilot study tested whether a combination of injectable naltrexone and oral bupropion could help people with schizophrenia who smoke cigarettes. Only 2 participants were enrolled before the study was terminated. The main goals were to see if the treatment was feasible a…

This study tested whether a non-invasive brain stimulation technique called TMS could help reduce negative symptoms of schizophrenia, like low motivation and reduced facial expression. The trial enrolled 47 adults with schizophrenia or schizoaffective disorder and compared active…

This study looked at whether adding cognitive remediation therapy (a type of brain training) to supported education (help returning to school) improves academic functioning in young adults with psychotic disorders. Only 9 people enrolled before the study was stopped early. The go…

This pilot study tested whether combining repetitive transcranial magnetic stimulation (rTMS) with computerized cognitive training could help adults with schizophrenia who have thinking and memory problems. Twelve participants received either active or sham rTMS followed by cogni…

This study looked at whether oxytocin, a natural brain chemical that helps with social bonding, could improve social functioning in veterans with schizophrenia. Researchers planned to give oxytocin and use brain scans to see who might benefit. The study was stopped early, so resu…

This study aimed to see if a simple eye scan could predict which people with early schizophrenia would benefit from a drug called sodium nitroprusside. The drug was given to reduce psychosis symptoms like delusions and hallucinations. Only one person enrolled before the study was…

This study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…

This study looked at how noninvasive brain stimulation techniques like rTMS, tDCS, and ECT change BDNF levels in people with depression or schizophrenia. Researchers took blood samples before and after stimulation to measure BDNF, a protein linked to brain health. The study was t…

This study tested a French version of a questionnaire that measures how much patients know about lithium, a drug used for bipolar and schizoaffective disorders. Researchers wanted to see if higher knowledge scores matched safe lithium levels in the blood. The study included 22 ho…

This study tested whether a non-invasive brain stimulation technique called deep rTMS could change brain activity and reduce smoking in people with schizophrenia. Researchers used brain scans to measure changes in brain connections and smoking behavior. The study was small and en…

This small, early study tested a new approach called Auditory Control Enhancement (ACE) for people with schizophrenia who hear voices (auditory hallucinations) that don't respond to medication. ACE combines a mild brain stimulation technique called tDCS with cognitive training. T…

This study tested a smartphone-based program to help veterans with serious mental illness (like PTSD, bipolar disorder, or schizophrenia) better recognize and describe their emotions. The goal was to see if improving emotion awareness could lower suicide risk. Only 11 veterans to…

This study aimed to compare the effects of clozapine versus other antipsychotic medications on inflammation in people with treatment-resistant schizophrenia. Researchers measured inflammatory markers like interleukin-6 in a small group of participants. The study was terminated ea…

This study looked at whether caregivers' negative beliefs about antipsychotic medications make it harder for people with schizophrenia to stick to their treatment. About 50 patients and their main caregivers answered questionnaires about medication beliefs and adherence. The goal…

This study looked at whether a digital platform called Horyzons could be used in clinics that help young people with early psychosis. The platform offers therapy content and a safe social network. Researchers wanted to understand what helps or hinders its use in real-world care. …